More from these Authors

• Article | JAMA, the Journal of the American Medical Association | September 15, 2020

  Moving the Financing of Graduate Medical Education Into the 21st Century

  Justin A. Grischkan, Ari B. Friedman and Amitabh Chandra

  Citation:

  Grischkan, Justin A., Ari B. Friedman, and Amitabh Chandra. "Moving the Financing of Graduate Medical Education Into the 21st Century." JAMA, the Journal of the American Medical Association 324, no. 11 (September 15, 2020).  View Details

  CiteView Details Read Now

  Related

• Article | JAMA, the Journal of the American Medical Association | September 8, 2020

  Allocation of COVID-19 Relief Funding to Disproportionately Black Counties

  Pragya Kakani, Amitabh Chandra and Sendhil Mullainathan

  This study describes correlations between the dollar amount of relief funding authorized by the US Congress to fund prevention, diagnosis, and treatment of coronavirus disease 2019 (COVID-19) and to reimburse health care entities for lost revenues, and county-level Black population fraction accounting for county COVID-19 burden, comorbidity, and hospital financial health.

  Keywords: COVID-19; Health Pandemics; Resource Allocation; Demographics; Race;

  Citation:

  Kakani, Pragya, Amitabh Chandra, and Sendhil Mullainathan. "Allocation of COVID-19 Relief Funding to Disproportionately Black Counties." JAMA, the Journal of the American Medical Association 324, no. 10 (September 8, 2020): 1000–1003.  View Details

  CiteView Details Read Now

  Related

• Article | NEJM Catalyst Innovations in Care Delivery | September–October 2020

  The Past, Present, and (Near) Future of Gene Therapy and Gene Editing

  Julia Pian, Amitabh Chandra and Ariel Dora Stern

  Emerging gene therapy and gene-editing technologies will have a growing impact on patient lives and health-care delivery. We analyzed a decade of data on clinical trials and venture capital investments to understand the likely trajectory of genetically focused therapies in the years ahead. The number of clinical trials and venture capital deals increased substantially from 2006–2017. We observed particularly notable growth in both industry-sponsored trials and trials involving specialty fields of drug development, including oncology, neurology, hematology, ophthalmology, and neurology. As the number of gene-therapy and gene-editing technologies continues to grow, we expect that such therapies will have a significant and heterogeneous impact on health-care delivery, including a shifting of resources from chronic disease management to more intense acute episodic care, an increase in the complexity of required intellectual property and manufacturing know-how, and the potential expansion of biopharmaceutical companies into service-based business models.

  Keywords: gene therapy; gene editing; Impact; Health Care and Treatment; Technological Innovation; Health Testing and Trials; Venture Capital; Change;

  Citation:

  Pian, Julia, Amitabh Chandra, and Ariel Dora Stern. "The Past, Present, and (Near) Future of Gene Therapy and Gene Editing." NEJM Catalyst Innovations in Care Delivery 1, no. 5 (September–October 2020).  View Details

  CiteView DetailsFind at Harvard Read Now

  Related